Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph3 Pembro + BCG High-risk Bladder View
Description: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Indication:
Bladder Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Brain Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 SY-1365 Solid Tumors View
Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Cervical Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Colon Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Esophageal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Nivo+Rucap Ovarian (ATHENA) View
Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Leukemia
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Liver Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Liver Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Adj canakinumab NSCLC View
Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View
Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph 1/1b Immunotherapy Combo in NSCLC View
Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View
Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR BV in older pts w/1L cHL or PTCL View
Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph3 R/R CLL/SLL View
Description: A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-3111-305)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Melanoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1/2 INCB001158 + SC Dara vs Dara SC MM View
Description: A Randomized Open-Label Phase 1/2 Study of INCB001158Combined With Subcutaneous (SC) Daratumumab, Compared toDaratumumab SC, in Participants With Relapsed or RefractoryMultiple Myeloma (INCB 01158-206)
Indication:
Myelomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Nivo+Rucap Ovarian (ATHENA) View
Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph1 SY-1365 Solid Tumors View
Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph3 Nivo+Rucap Ovarian (ATHENA) View
Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
Ph3 TSR-042, Niraparib Ovarian FIRST View
Description: 3000-03-005/ENGOT-OV44 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINE TREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: III
Title:
STAR Abirat+pred +/- abemaciclib mCRPC View
Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Rectal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph2 INCMGA00012 mSCAC View
Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)
Indication:
Rectal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Renal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 MSB0011359C Solid Tumors View
Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1 SY-1365 Solid Tumors View
Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
Ph1b/2 Copanlisib+Nivo Solid Tumors View
Description: An open-label, multi-center, phase 1b/2 study to evaluate thesafety and efficacy of copanlisib in combination with nivolumabin patients with advanced solid tumors (19769)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I/II
Title:
Ph1 Solid tumors, RCC, mCRPC View
Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: I
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II